OmniAb (NASDAQ:OABI – Get Free Report) and Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Profitability
This table compares OmniAb and Achieve Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -187.59% | -20.31% | -18.10% |
| Achieve Life Sciences | N/A | -193.49% | -111.88% |
Earnings & Valuation
This table compares OmniAb and Achieve Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $18.67 million | 18.38 | -$64.78 million | ($0.46) | -5.15 |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.12) | -3.97 |
Achieve Life Sciences has lower revenue, but higher earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
OmniAb has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for OmniAb and Achieve Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 2 | 0 | 2.33 |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
OmniAb presently has a consensus price target of $3.00, indicating a potential upside of 26.58%. Achieve Life Sciences has a consensus price target of $14.67, indicating a potential upside of 229.59%. Given Achieve Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than OmniAb.
Summary
Achieve Life Sciences beats OmniAb on 8 of the 14 factors compared between the two stocks.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
